PMV Pharmaceuticals, Inc.
PMVPDrugs in Pipeline
1
Phase 3 Programs
0
Upcoming Catalysts
2
Next Catalyst
Aug 6, 2026
TomorrowMarket Overview
Stock performance and key metrics
2 upcoming, 0 past
PMVP Earnings Report
EPS Est: $-0.38 | FQ end 2026-06
rezatapopt Phase 2 Est. Readout
Primary completion for rezatapopt trial (NCT04585750) in Advanced Solid Tumor
SourceHow PMVP's past catalysts played out
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
rezatapopt | Phase 2 | Advanced Solid Tumor | - | - |
Full breakdown — the signals behind the verdict
Frequently asked questions
What is in PMV Pharmaceuticals, Inc.'s drug pipeline?→
CatalystAlert tracks 1 drug candidate in PMV Pharmaceuticals, Inc.'s (PMVP) pipeline across Phase 2. Its lead program is rezatapopt (Phase 2). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is PMV Pharmaceuticals, Inc.'s next FDA catalyst?→
PMV Pharmaceuticals, Inc.'s (PMVP) next tracked catalyst is a Earnings expected August 6, 2026. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track PMVP biotech catalysts?→
Add PMVP to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow PMV Pharmaceuticals, Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.